Core Viewpoint - Furuya Medical Technology (01696) experienced a significant decline of over 11%, with a current price of HKD 6.18 and a trading volume of HKD 18.245 million following the release of its mid-year results for 2025, indicating challenges in the North American market and a decrease in profitability [1][1][1] Financial Performance - The company reported revenues of USD 165 million for the mid-year period, reflecting a year-on-year decrease of 1.9% [1] - Net profit attributable to shareholders was USD 6.426 million, down 41.3% year-on-year [1] - Basic earnings per share were USD 0.0137 [1] Market Conditions - The decline in revenue is primarily attributed to challenging conditions in the North American market, characterized by high interest rates and weak consumer demand [1] - Transportation delays due to regional tensions in June also contributed to a slight delay in revenue recognition [1] International Market Growth - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Order Reserves and Profitability - As of June 30, 2025, the company's order reserves remained robust, increasing by several million dollars compared to the same period in 2024 [1] - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period, primarily due to a strategic shift towards core professional and high-end products, which have higher material costs due to advanced technology specifications [1][1]

复锐医疗科技(01696)发布截至2025年6月30日止六个月业绩，收益1.65亿美元，同比下降1.9%;母公司拥 有人应占溢利642.6万美元，同比下降41.3%;每股基本盈利1.37美仙。 期内，集团收益同比减少，主要归因于北美市场状况充满挑战，包括高利率及消费疲软。此外，六月因 地区紧张局势令运输受限，导致收益确认略有延迟。若不计北美市场不利因素，与2024年同期相比，复 锐医疗科技国际市场实现7.1%增长。截至2025年6月30日，订单储备保持稳健，较2024年同期增加数百 万美元。 毛利率由2024年同期的62.4%减少至报告期的60.0%。减少主要归因于产品组合战略性倾向核心专业级 及精密的高端产品，该类产品因采用顶尖技术规格而导致物料成本上升，同时受北美收益占比下降影 响。 ...

毛利率由2024年同期的62.4%减少至报告期的60.0%。减少主要归因于产品组合战略性倾向核心专业级 及精密的高端产品，该类产品因采用顶尖技术规格而导致物料成本上升，同时受北美收益占比下降影 响。 智通财经APP讯，复锐医疗科技(01696)发布截至2025年6月30日止六个月业绩，收益1.65亿美元，同比 下降1.9%;母公司拥有人应占溢利642.6万美元，同比下降41.3%;每股基本盈利1.37美仙。 期内，集团收益同比减少，主要归因于北美市场状况充满挑战，包括高利率及消费疲软。此外，六月因 地区紧张局势令运输受限，导致收益确认略有延迟。若不计北美市场不利因素，与2024年同期相比，复 锐医疗科技国际市场实现7.1% 增长。截至2025年6月30日，订单储备保持稳健，较2024年同期增加数百 万美元。 ...